% | $
Quotes you view appear here for quick access.

Rosetta Genomics, Ltd. Message Board

  • panalta2000 panalta2000 May 19, 2012 7:44 PM Flag

    So they now have 1.8 MM shares OS and $3 million cash

    1.89 MM shares OS, $1.8 cash per share and 0 debt.

    Back out the cash, ROSG still only valued at $8 million.
    I like this.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    •, have issue a confimed BUY on the stock and a do not even blink.This will explode to the upside like you have never seen in a long time.

    • The question is not adding institutional investores as they won't look at such a tiny microcap in most cases. The question for us longs is when to start cashing out? To me the best way to figure it is to look at market cap. If you conservativly figure 20,000 tests at a Medicare reimbursement rate of $2k that is $40M in sales. So a conservative 1x sales equates to a $20 stock. Would anyone be considered greedy to hold for that kind of market cap??

      • 3 Replies to flrebroker1
      • I don't see 20 as a selling point. I see ROSG as a long term hold as long as they are making progress on the sales. I'm having to hold to next year anyway due to the amount of the gains.

        Teaming up with a decent sales force will be likely or a buyout at current low valuations.

        One should take great notice in the trading volume. We are trading the float or more every session. This points to a stock going much higher from here.


      • good analysis and conservative too

        2k reimbursement rate when the company mentioned in the article has a reimbursement rate of $3500

        that's the next bomb to drop; the pr said they would get the reimbursement rate soon from medicare

        only problem is how do they get to 20k sales?

        the negative i saw in the article is rosg only has a sales force of 4!

        they're going to have to sell their butts off to get to 20k sales or imcrease their sales force

        also, what are the margins?
        let's say the reimbursement rate is 2k

        what does it cost to make the kit?

        1k, couple of hundred bucks?

        dndn for example sells provenge for 96k but it costs them over 80k to make because it's so labor entensive

        how do you get to 20k sales and of that 20k, how much is profit?

        one other thing; the secondary is priced on the 22nd; depending on how the secondary is structured, we might/should see sec filings showing who the new buyers are if they own >5% of the company

        i'm really curious who the buyers are

        also, i don't expect those shrs to hit the market, i don't think they're going to buy in for 3.50 and flip'em for a quick double

        they're in for bigger gains

        this is going to be real interesting to watch

        gene ran from .86 to over 9 on their test kit and then crashed when they screwed up their secondary and their float was 14k or so

        agree with you in that double digits is the near term target and then everyone has to decide what to do


    • They are going to burn the cash in no time. No revenues to speak of and now they need to market the test.

0.63-0.01(-1.53%)Oct 27 3:54 PMEDT